Literature DB >> 30735435

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

Ken Kato1, Manish A Shah2, Peter Enzinger3, Jaafar Bennouna4, Lin Shen5, Antoine Adenis6, Jong-Mu Sun7, Byoung Chul Cho8, Mustafa Özgüroğlu9, Takashi Kojima10, Vladimir Kostorov11, Cinta Hierro12, Ying Zhu13, Lee Anne McLean13, Sukrut Shah13, Toshihiko Doi10.   

Abstract

BACKGROUND: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. AIM: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719.

Entities:  

Keywords:  PD-1; PD-L1; chemotherapy; esophageal cancer; esophagogastric junction cancer; gastrointestinal/esophageal; immunotherapy; pembrolizumab; squamous cell carcinoma of the esophagus

Mesh：

Substances：

Year:  2019        PMID： 30735435     DOI： 10.2217/fon-2018-0609

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  47 in total

1.  Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway.

Authors:  Wei Zhang; Ankur S Bhagwath; Zeeshan Ramzan; Taylor A Williams; Indhumathy Subramaniyan; Vindhya Edpuganti; Raja Reddy Kallem; Kerry B Dunbar; Peiguo Ding; Ke Gong; Samuel A Geurkink; Muhammad S Beg; James Kim; Qiuyang Zhang; Amyn A Habib; Sung-Hee Choi; Ritu Lapsiwala; Gayathri Bhagwath; Jonathan E Dowell; Shelby D Melton; Chunfa Jie; William C Putnam; Thai H Pham; David H Wang
Journal:  Mol Cancer Ther       Date:  2021-08-10       Impact factor: 6.261

2.  Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma.

Authors:  Zibin Liang; Xiaojian Li; Bingjiang Huang; Haiyan Shi; Xiaohua Gong; Jing Yu; Caixia Xiao; Bin Zhou
Journal:  J Gastrointest Oncol       Date:  2021-10

3.  Effects of Radiotherapy on Survival of Esophageal Cancer Patients Receiving Immunotherapy: Propensity Score Analysis and Nomogram Construction.

Authors:  Yuanliu Nie; Guangyue Yao; Liang Li; Alei Feng; Wentao Zhang; Xiaoying Xu; Qiang Li; Zhe Yang
Journal:  Cancer Manag Res       Date:  2022-08-07       Impact factor: 3.602

4.  Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world.

Authors:  Pei Zhang; Xiaobin Hou; Boning Cai; Wei Yu; Jing Chen; Xiang Huang; Ye Li; Mingyue Zeng; Zhipeng Ren; Emmanuel Gabriel; Baolin Qu; Fang Liu
Journal:  Ann Transl Med       Date:  2022-06

Review 5.  Emerging role of circulating tumor cells in immunotherapy.

Authors:  Alexey Rzhevskiy; Alina Kapitannikova; Polina Malinina; Arthur Volovetsky; Hamidreza Aboulkheyr Es; Arutha Kulasinghe; Jean Paul Thiery; Anna Maslennikova; Andrei V Zvyagin; Majid Ebrahimi Warkiani
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

Review 6.  Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.

Authors:  Yoshihiro Kakeji; Taro Oshikiri; Gosuke Takiguchi; Shingo Kanaji; Takeru Matsuda; Tetsu Nakamura; Satoshi Suzuki
Journal:  Esophagus       Date:  2020-09-22       Impact factor: 4.230

Review 7.  Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.

Authors:  Jasmine Huynh; Kanishka Patel; Jun Gong; May Cho; Midhun Malla; Aparna Parikh; Samuel Klempner
Journal:  Curr Treat Options Oncol       Date:  2021-09-15

Review 8.  Understanding the cellular origin and progression of esophageal cancer using esophageal organoids.

Authors:  Uma M Sachdeva; Masataka Shimonosono; Samuel Flashner; Ricardo Cruz-Acuña; Joel T Gabre; Hiroshi Nakagawa
Journal:  Cancer Lett       Date:  2021-04-07       Impact factor: 9.756

9.  Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report.

Authors:  Dianne Barrett; Andrew Sumnicht; K V Chalam; Micheal Rauser
Journal:  Oxf Med Case Reports       Date:  2021-06-18

10.  Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma.

Authors:  Zhigang Wu; Qiang Zheng; Haiquan Chen; Jiaqing Xiang; Hong Hu; Hang Li; Yunjian Pan; Yizhou Peng; Xingxin Yao; Pengcheng Liu; Yihua Sun; Bin Li; Yawei Zhang
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.